Literature DB >> 22948942

miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells.

Shuai Huang1, Wei Guo, Yubo Tang, Dong Ren, Xuenong Zou, Xinsheng Peng.   

Abstract

Emerging evidence demonstrates that cancer stem cells (CSCs) are the critical drivers of tumor progression and metastasis. The microRNAs (miRNAs) may play a crucial role in repressing/promoting metastasis of cancer by regulating CSCs. A previous study showed that miR-143 and miR-145 play an important role in regulating bone metastasis of prostate cancer (PCa), but the exact mechanism of regulation of bone metastasis of PCa is not fully understood. In this study, we found that overexpression of miR-143 and miR-145 inhibited the cell viability and colony formation of PC-3 cells from PCa bone metastasis. Furthermore, miR-143 and miR-145 suppressed tumor sphere formation and expression of CSC markers and 'stemness' factors including CD133, CD44, Oct4, c-Myc and Klf4 in PC-3 cells. The study further found that miR-143 and miR-145 inhibit bone invasion and tumorigenicity of PC-3 cells in vivo. Collectively, these findings demonstrate that miR-143 and miR-145 inhibit CSC properties of PC-3 cells and suggest that miR-143 and miR-145 may play a significant role in the bone metastasis progression of PCa by regulating CSC characteristics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948942     DOI: 10.3892/or.2012.2015

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  54 in total

1.  MicroRNAs used as novel biomarkers for detecting cancer metastasis.

Authors:  Chunshan Han; Haixiang Yu; Lening Zhang; Xiaoli Li; Yonggang Feng; Hua Xin
Journal:  Tumour Biol       Date:  2014-10-31

Review 2.  The roles of microRNAs in the progression of castration-resistant prostate cancer.

Authors:  Satoko Kojima; Yusuke Goto; Yukio Naya
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

3.  miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition.

Authors:  Hong Zhao; Xing Kang; Xuefeng Xia; Like Wo; Xidong Gu; Yuanyuan Hu; Xiaohong Xie; Helena Chang; Lihua Lou; Xuning Shen
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

4.  Mitigation of arsenic-induced acquired cancer phenotype in prostate cancer stem cells by miR-143 restoration.

Authors:  Ntube N O Ngalame; Ngome L Makia; Michael P Waalkes; Erik J Tokar
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-22       Impact factor: 4.219

Review 5.  MicroRNAs targeting prostate cancer stem cells.

Authors:  Yu-Xiang Fang; Yun-Li Chang; Wei-Qiang Gao
Journal:  Exp Biol Med (Maywood)       Date:  2015-05-12

6.  The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer.

Authors:  Satoko Kojima; Hideki Enokida; Hirofumi Yoshino; Toshihiko Itesako; Takeshi Chiyomaru; Takashi Kinoshita; Miki Fuse; Rika Nishikawa; Yusuke Goto; Yukio Naya; Masayuki Nakagawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2013-11-28       Impact factor: 3.172

Review 7.  Environmental exposures, stem cells, and cancer.

Authors:  Tasha Thong; Chanese A Forté; Evan M Hill; Justin A Colacino
Journal:  Pharmacol Ther       Date:  2019-07-31       Impact factor: 12.310

Review 8.  MicroRNA mediated therapeutic effects of natural agents in prostate cancer.

Authors:  Km Anjaly; A B Tiku
Journal:  Mol Biol Rep       Date:  2021-07-24       Impact factor: 2.316

9.  MiRNA regulation of TRAIL expression exerts selective cytotoxicity to prostate carcinoma cells.

Authors:  Wei Huo; Ning Jin; Li Fan; Weihua Wang
Journal:  Mol Cell Biochem       Date:  2013-11-30       Impact factor: 3.396

10.  Androgen receptor expands the population of cancer stem cells in upper urinary tract urothelial cell carcinoma cells.

Authors:  Chi-Cheng Chen; Teng-Fu Hsieh; Chi-Ping Huang; Ai-Lin Yu; Wen-Lin Chang; Chih-Rong Shyr
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.